Lung Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Lung Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Lung Cancer Therapeutics Market

The Lung Cancer Therapeutics market size was valued at USD 18.327 billion in 2018, and the market is now projected to grow from USD 18.327 billion in 2018 to USD 104.269 billion by 2032, exhibiting a CAGR of 13.3% during the forecast period of 2023-2030.

The COVID-19 pandemic appreciably impacted the Lung Cancer Therapeutics market growth by disrupting patient care, treatment regimens, and clinical trials. During the pandemic, healthcare systems prioritised COVID-19 instances, leading to delays in most cancer screenings, diagnostic methods, and non-compulsory treatments, which are important for early detection and timely intervention in lung cancer. Many sufferers avoided health centre visits due to the risk of contamination, resulting in ignored or postponed treatments, inclusive of surgeries, chemotherapy, and radiation therapy. Clinical trials for new lung cancer treatment options faced interruptions due to lockdowns, limited movement, and challenges in affected person recruitment and monitoring, delaying the progress of revolutionary therapeutics. Supply chain disruptions additionally affected the supply of essential tablets and scientific equipment.

Increasing adoption and call for centred treatment plans, which is considered to be the foundation of precision medication due to the increasing Research and Development tasks, is one of the most prominent driving factors for the increase of the global Lung Cancer Therapeutics market share in 2018. The focused remedy section is anticipated to have the most important marketplace proportion amongst remedy kinds. The focused remedy phase accounted for a market percentage of 51.1% in 2018 and is anticipated to push upward all through the forecast period. Increasing consciousness in the direction of the analysis of lung cancer and the subsequent treatment based on the correct targeting of the tumour or the supply of most cancers is likewise using the increase inside the targeted therapy segment.

Additionally, rise in most cancers recognition in both developing and evolved nations, and the emergence of recent clinical diagnostic equipment and superior therapeutics have multiplied the wide variety of lung most cancers diagnoses, as a result propelling the lung cancer therapeutics marketplace boom. This, coupled with, increasing investments by using foremost players in studies and development sports is also boosting the worldwide marketplace increase.

Comprehensive Analysis of Lung Cancer Therapeutics Market

Based on the remedy, the lung cancers therapeutics market segments consist of centred therapy (which may be similarly sub-segmented into bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, osimertinib, and others), hormonal therapy (which can be similarly sub-segmented durvalumab, nivolumab, atezolizumab, pembrolizumab), and chemotherapy. The focused remedy segment dominated the worldwide marketplace in 2018. The phase accounted for 51.1% proportion of the market share in 2018. Based on distribution channels, the worldwide market segments encompass sanatorium pharmacies, retail pharmacies, online pharmacies, and others. Based on cancer type, the lung most cancers therapeutics marketplace segments consist of non-small cellular lung cancer (NSCLC) and small cell lung most cancers (SCLC).

North America generated a lung most cancers therapeutics marketplace sales of US$ 8,093.2 Mn in 2018 and is predicted to account for a dominant share within the international marketplace during the forecast period. Growth witnessed inside the place is probably to be pushed using the growing adoption of advanced lung cancer therapeutics and the rising prevalence and diagnoses of most lung cancers.

The top players in the market play a crucial role in the healthcare industry, assuring industrial prospectus growth and setting market standards. These players include Genentech (F. Hoffmann-La Roche Ltd) (U.S.), Eli Lilly and Company (U.S.), Celgene Corporation (U.S.), AstraZeneca (U.K.), Pfizer Inc. (U.S.), Sanofi (France), Novartis AG (Switzerland), Astellas Pharma Inc. (Japan) and Bristol Myers Squibb (U.S.); these market players provide a level-playing competitive landscape.

In March 2019, Adorx Therapeutics Limited. introduced that it had entered right into a strategic partnership with Johnson and Johnson Innovation LLC and Lung Cancer Initiative at Johnson and Johnson (LCI) for the development of the latest novel lung cancer therapeutics.

Segmentation Table

Global Lung Cancer Therapeutics Market Scope

Study Period 2019-2032

Base Year 2023

Forecast Period 2019-2026

Growth Rate CAGR of 13.3% from 2024-2032

Historical Period 2019-2022

Unit Value (USD Billion)

Segmentation By Therapy, cancer type, distribution channel and Region

By Therapy

Targeted Therapy

Bevacizumab

Dabrafenib/Trametinib

Erlotinib Hydrochloride

Osimertinib

Others

Immunotherapy

Durvalumab

Nivolumab

Atezolizumab

Pembrolizumab

Chemotherapy

By cancer type

Non-small cell lung cancer (NSCLC)

Small cell lung cancer (SCLC)

By distribution channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

By Region

North America (U.S., and Canada)

Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and the Rest of Latin America)

Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)